Our results against Beta-CoVs, including notably NeoCoV, can now be of guiding towards the design and development of a Universal Beta-CoVs Vaccine considering the knowledge of antigenic regions from Spike and other structural proteins we recover from available cross-neutralizing antibodies in the human serum samples we tested.